Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

New clotting cofactor-binding anticoagulant RNA aptamers presented

Oct. 11, 2021

Phase II trial of roxadustat for chemotherapy-induced anemia meets primary efficacy endpoint

Aug. 25, 2021

InnoCare receives NMPA clearance for phase II study of orelabrutinib in ITP

Aug. 11, 2021

China's NMPA approves IND for phase I/II study of BBM-H901

Aug. 11, 2021

Positive interim data presented from phase I study of FTX-6058

Aug. 11, 2021

KV-998083 effective in models of thrombosis and vascular leakage

July 30, 2021

First-in-human study investigates HJV inhibitor DISC-0974 for anemia of inflammation

July 28, 2021

FXa-DOAC reversal with no thrombogenic potential seen with VMX-C001

July 28, 2021

ExCellThera initiates phase I study of ECT-001-CB in sickle cell disease

July 23, 2021

Chinese researchers patent coagulation factor XIa inhibitors

July 23, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...